You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEstrone
Accession NumberDB00655  (APRD00588)
TypeSmall Molecule
GroupsApproved
DescriptionEstrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
Structure
Thumb
Synonyms
3-Hydroxy-1,3,5(10)-estratrien-17-one
Estrona
Estrone
Estronum
follicular hormone
Folliculin
Oestrone
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Estragyn Vaginal Creamcream0.1 %vaginalSearchlight Pharma Inc1987-12-31Not applicableCanada
Oestrilin Cones Vaginauxsuppository.25 mgvaginalDesbergers LtÉe, Division Of Technilab Inc.1951-12-312004-08-09Canada
Oestrilin Creme Vaginale 1mgcream1 mgvaginalDesbergers LtÉe, Division Of Technilab Inc.1968-12-312004-08-23Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EstroneWatson
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2DI9HA706A
CAS number53-16-7
WeightAverage: 270.3661
Monoisotopic: 270.161979948
Chemical FormulaC18H22O2
InChI KeyInChIKey=DNXHEGUUPJUMQT-CBZIJGRNSA-N
InChI
InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1
IUPAC Name
(1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-14-one
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrogens and derivatives
Alternative Parents
Substituents
  • Estrogen-skeleton
  • Oxosteroid
  • 17-oxosteroid
  • Hydroxysteroid
  • 3-hydroxysteroid
  • Phenanthrene
  • Tetralin
  • Benzenoid
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor management of perimenopausal and postmenopausal symptoms.
PharmacodynamicsEstrone, a synthetically prepared or naturally occurring steroidal estrogen obtained from pregnant equine urine, is the primary circulating estrogen after menopause. Estrone is naturally derived from the peripheral conversion of androstenedione by an aromatase enzyme found in adipose tissues and is converted to estradiol in peripheral tissues. The estrogenic potency of estrone is one third that of estradiol. Estropipate is piperazine-stabilized estrone sulfate. Estrone, and estropipate are used to treat abnormalities related to gonadotropin hormone dysfunction, vasomotor symptoms, atrophic vaginitis, and vulvar atrophy associated with menopause, and for the prevention of osteoporosis due to estrogen deficiency.
Mechanism of actionEstrogens enter the cells of responsive tissues (e.g. female organs, breasts, hypothalamus, pituitary) where they interact with estrogen receptors. Hormone-bound estrogen receptors dimerize, translocate to the nucleus of cells and bind to estrogen response elements (ERE) of genes. Binding to ERE alters the transcription rate of affected genes. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) release from the anterior pituitary.
Related Articles
Absorption43%
Volume of distributionNot Available
Protein binding> 95%
Metabolism

Hepatic.

SubstrateEnzymesProduct
Estrone
2-hydroxyestroneDetails
Estrone
4-hydroxyestroneDetails
Estrone
Not Available
Estrone sulfateDetails
Estrone
Not Available
Estrone glucuronideDetails
Estrone
Not Available
2-Hydroxyestrone sulfateDetails
Estrone
Not Available
4-Hydroxyestrone sulfateDetails
Route of eliminationNot Available
Half life19 hours
ClearanceNot Available
ToxicitySymptoms of overdose include nausea and vomiting. Estrogen related side effects include nausea, breast tenderness, fluid retention and edema, headaches and/or migraines, chloasma and poor contact lens fit. Estrogen hormone deficiency is associated with breakthrough bleeding, hypomenorrhea, irritability, depression and menopausal symptoms. Withdrawal bleeds may occur in females.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDiseaseSMP00356
Androgen and Estrogen MetabolismMetabolicSMP00068
Sulfate/Sulfite MetabolismMetabolicSMP00041
Sulfite oxidase deficiencyDiseaseSMP00532
Aromatase deficiencyDiseaseSMP00565
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9529
Caco-2 permeable+0.8934
P-glycoprotein substrateSubstrate0.6001
P-glycoprotein inhibitor INon-inhibitor0.9066
P-glycoprotein inhibitor IINon-inhibitor0.8882
Renal organic cation transporterNon-inhibitor0.73
CYP450 2C9 substrateNon-substrate0.6624
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.729
CYP450 1A2 substrateInhibitor0.9017
CYP450 2C9 inhibitorNon-inhibitor0.9353
CYP450 2D6 inhibitorNon-inhibitor0.9599
CYP450 2C19 inhibitorNon-inhibitor0.8954
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8681
Ames testNon AMES toxic0.9268
CarcinogenicityNon-carcinogens0.8917
BiodegradationNot ready biodegradable0.9717
Rat acute toxicity1.9267 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8711
hERG inhibition (predictor II)Inhibitor0.5459
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth ayerst laboratories
  • Watson laboratories inc
  • Parkedale pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Creamvaginal0.1 %
Suppositoryvaginal.25 mg
Creamvaginal1 mg
Prices
Unit descriptionCostUnit
Estrone powder21.42USD g
Estrone crystal11.76USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point260.2 °CPhysProp
boiling point154 °CPhysProp
water solubility30 mg/L (at 25 °C)MERCK INDEX (1996)
logP3.13HANSCH,C ET AL. (1995)
logS-3.96ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.00394 mg/mLALOGPS
logP4.03ALOGPS
logP4.31ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.33ChemAxon
pKa (Strongest Basic)-5.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity79.08 m3·mol-1ChemAxon
Polarizability31.27 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.95 KB)
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-MS (1 TMS)splash10-05ox-3951000000-8bc438f505b3cf49b21fView in MoNA
GC-MSGC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)splash10-003u-4942000000-a72ea34d85d9d524c247View in MoNA
GC-MSGC-MS Spectrum - GC-MS (1 MEOX; 1 TMS)splash10-0019-8931000000-aad9803af812c7c40f53View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)splash10-00di-0190000000-071e67516e11357ff64eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)splash10-0a4j-4910000000-20e059a7c508ba492af3View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)splash10-067i-9700000000-9ff5214f08822f238fa9View in MoNA
LC-MS/MSLC-MS/MS Spectrum - EI-B (HITACHI M-80) , Positivesplash10-00di-2940000000-3b9744c27d6a3d2eff6eView in MoNA
MSMass Spectrum (Electron Ionization)splash10-00di-2930000000-c99df908474247066a2bView in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
References
Synthesis Reference

Seiichi Takano, Kunio Ogasawara, “Method for producing (+)-estrone derivatives.” U.S. Patent US5424462, issued January, 1965.

US5424462
General References
  1. Miyoshi Y, Tanji Y, Taguchi T, Tamaki Y, Noguchi S: Association of serum estrone levels with estrogen receptor-positive breast cancer risk in postmenopausal Japanese women. Clin Cancer Res. 2003 Jun;9(6):2229-33. [PubMed:12796390 ]
  2. Kajta M, Lason W, Bien E, Marszal M: Neuroprotective effects of estrone on NMDA-induced toxicity in primary cultures of rat cortical neurons are independent of estrogen receptors. Pol J Pharmacol. 2002 Nov-Dec;54(6):727-9. [PubMed:12866733 ]
External Links
ATC CodesG03CA07G03CC04
AHFS Codes
  • 68:16.04
  • 92:02.00*
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (76.2 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Estrone is combined with 1,10-Phenanthroline.
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be increased when it is combined with Estrone.
AbciximabEstrone may decrease the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Estrone can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Estrone.
AcenocoumarolEstrone may decrease the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Estrone.
AcetaminophenThe serum concentration of Estrone can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Estrone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Estrone.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Estrone.
AfatinibThe serum concentration of Estrone can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Estrone can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Estrone.
AldesleukinEstrone may decrease the antineoplastic activities of Aldesleukin.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Estrone.
AldosteroneThe serum concentration of Estrone can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Estrone can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Estrone can be increased when it is combined with Alfentanil.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Estrone.
Aluminum hydroxideThe bioavailability of Estrone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Estrone can be decreased when combined with Aluminum phosphate.
AmantadineThe serum concentration of Estrone can be increased when it is combined with Amantadine.
AmbenoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Ambenonium.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Estrone.
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Estrone.
Aminohippuric acidThe serum concentration of Estrone can be increased when it is combined with Aminohippuric acid.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Estrone.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Estrone.
AmiodaroneThe serum concentration of Estrone can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Estrone.
AmitriptylineThe serum concentration of Estrone can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Estrone can be increased when it is combined with Amlodipine.
Amphotericin BEstrone may increase the hypokalemic activities of Amphotericin B.
AmprenavirThe serum concentration of Estrone can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Estrone can be increased when it is combined with Amsacrine.
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone.
AncrodEstrone may decrease the anticoagulant activities of Ancrod.
Anthrax immune globulin humanEstrone may increase the thrombogenic activities of Anthrax immune globulin human.
Antithrombin III humanEstrone may decrease the anticoagulant activities of Antithrombin III human.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Estrone.
AprepitantThe serum concentration of Estrone can be increased when it is combined with Aprepitant.
ArdeparinEstrone may decrease the anticoagulant activities of Ardeparin.
ArgatrobanEstrone may decrease the anticoagulant activities of Argatroban.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Estrone.
AstemizoleThe serum concentration of Estrone can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Estrone.
AtazanavirThe serum concentration of Estrone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Estrone.
AtenololThe serum concentration of Estrone can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Estrone can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Estrone can be increased when it is combined with Atorvastatin.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Estrone.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Estrone.
AzelastineThe serum concentration of Estrone can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Estrone can be increased when it is combined with Azithromycin.
BazedoxifeneThe serum concentration of Estrone can be increased when it is combined with Bazedoxifene.
BecaplerminEstrone may decrease the anticoagulant activities of Becaplermin.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Estrone.
BendroflumethiazideEstrone may increase the hypokalemic activities of Bendroflumethiazide.
BenzocaineThe serum concentration of Estrone can be increased when it is combined with Benzocaine.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Estrone.
BepridilThe serum concentration of Estrone can be increased when it is combined with Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Estrone.
BexaroteneThe serum concentration of Estrone can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Estrone can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe bioavailability of Estrone can be decreased when combined with Bismuth Subcitrate.
BivalirudinEstrone may decrease the anticoagulant activities of Bivalirudin.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Estrone.
BoceprevirThe serum concentration of Estrone can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Estrone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Estrone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Estrone.
BosutinibThe serum concentration of Estrone can be increased when it is combined with Bosutinib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Estrone.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Estrone.
BromocriptineThe serum concentration of Estrone can be increased when it is combined with Bromocriptine.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Estrone.
BumetanideEstrone may increase the hypokalemic activities of Bumetanide.
BuprenorphineThe serum concentration of Estrone can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Estrone can be increased when it is combined with Buspirone.
C1 Esterase Inhibitor (Human)Estrone may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Estrone may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Estrone.
CabazitaxelThe serum concentration of Estrone can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Estrone.
CaffeineThe serum concentration of Estrone can be increased when it is combined with Caffeine.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Estrone.
Calcium carbonateThe bioavailability of Estrone can be decreased when combined with Calcium carbonate.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Estrone.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Estrone.
CanagliflozinThe serum concentration of Estrone can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Estrone can be increased when it is combined with Candesartan.
CapecitabineThe metabolism of Estrone can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Estrone can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Estrone can be decreased when it is combined with Carbamazepine.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Estrone.
CarvedilolThe serum concentration of Estrone can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Estrone can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Estrone can be increased when it is combined with Ceritinib.
CeritinibEstrone may increase the hyperglycemic activities of Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Estrone.
CertoparinEstrone may decrease the anticoagulant activities of Certoparin.
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Estrone.
ChloroquineThe serum concentration of Estrone can be increased when it is combined with Chloroquine.
ChlorothiazideEstrone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Estrone can be increased when it is combined with Chlorotrianisene.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Estrone.
ChlorpromazineThe serum concentration of Estrone can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Estrone can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Estrone can be increased when it is combined with Chlorprothixene.
ChlorthalidoneEstrone may increase the hypokalemic activities of Chlorthalidone.
CholecalciferolThe metabolism of Estrone can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Estrone can be increased when it is combined with Cholesterol.
CholestyramineCholestyramine can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidThe serum concentration of Estrone can be decreased when it is combined with Cholic Acid.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Estrone.
CilazaprilThe serum concentration of Estrone can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Estrone can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Estrone.
CiprofloxacinThe serum concentration of Estrone can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Estrone.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Estrone.
CitalopramThe serum concentration of Estrone can be increased when it is combined with Citalopram.
Citric AcidEstrone may decrease the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Estrone.
ClarithromycinThe serum concentration of Estrone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Estrone can be decreased when combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Estrone.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Estrone.
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Estrone.
ClofazimineThe serum concentration of Estrone can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Estrone.
ClomipramineThe serum concentration of Estrone can be increased when it is combined with Clomipramine.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Estrone.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Estrone.
ClopidogrelThe metabolism of Estrone can be decreased when combined with Clopidogrel.
ClotrimazoleThe metabolism of Estrone can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Estrone.
CobicistatThe serum concentration of Estrone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Estrone.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Estrone.
ColchicineThe serum concentration of Estrone can be increased when it is combined with Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Estrone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColforsinThe serum concentration of Estrone can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Estrone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Estrone can be increased when it is combined with Conjugated Equine Estrogens.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Estrone.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Estrone.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Estrone.
CoumaphosThe risk or severity of adverse effects can be increased when Estrone is combined with Coumaphos.
CrizotinibThe metabolism of Estrone can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Estrone.
CyclophosphamideThe serum concentration of Estrone can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Estrone can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Estrone.
Cyproterone acetateThe serum concentration of Estrone can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Estrone.
DabrafenibThe serum concentration of Estrone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Estrone can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Estrone.
DactinomycinThe serum concentration of Estrone can be increased when it is combined with Dactinomycin.
DalteparinEstrone may decrease the anticoagulant activities of Dalteparin.
DanaparoidEstrone may decrease the anticoagulant activities of Danaparoid.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Estrone.
DarunavirThe serum concentration of Estrone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Estrone can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Estrone.
DaunorubicinThe serum concentration of Estrone can be decreased when it is combined with Daunorubicin.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Estrone.
DecamethoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Decamethonium.
DeferasiroxThe serum concentration of Estrone can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Estrone is combined with Deferasirox.
DehydroepiandrosteroneThe risk or severity of adverse effects can be increased when Dehydroepiandrosterone is combined with Estrone.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Estrone.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Estrone.
DelavirdineThe metabolism of Estrone can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Estrone is combined with Demecarium.
DesipramineThe serum concentration of Estrone can be increased when it is combined with Desipramine.
DesirudinEstrone may decrease the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Estrone can be increased when it is combined with Desloratadine.
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Estrone.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Estrone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Estrone.
DexamethasoneThe serum concentration of Estrone can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Estrone.
DextranEstrone may decrease the anticoagulant activities of Dextran.
Dextran 40Estrone may decrease the anticoagulant activities of Dextran 40.
Dextran 70Estrone may decrease the anticoagulant activities of Dextran 70.
Dextran 75Estrone may decrease the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Estrone can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Estrone.
DichlorvosThe risk or severity of adverse effects can be increased when Estrone is combined with Dichlorvos.
DiclofenacThe serum concentration of Estrone can be increased when it is combined with Diclofenac.
DicoumarolEstrone may decrease the anticoagulant activities of Dicoumarol.
DienestrolThe serum concentration of Estrone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Estrone can be increased when it is combined with Diethylstilbestrol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Estrone.
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Estrone.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone.
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Estrone.
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Estrone.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Estrone.
DigoxinThe serum concentration of Estrone can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Estrone can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneEstrone may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Estrone can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Estrone.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Estrone.
DipyridamoleThe serum concentration of Estrone can be increased when it is combined with Dipyridamole.
DisulfiramThe metabolism of Estrone can be decreased when combined with Disulfiram.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Estrone.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Estrone.
DonepezilThe risk or severity of adverse effects can be increased when Estrone is combined with Donepezil.
DoxazosinThe serum concentration of Estrone can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Estrone can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Estrone can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Estrone can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Estrone can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Estrone can be decreased when combined with Dronedarone.
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Estrone.
EchothiophateThe risk or severity of adverse effects can be increased when Estrone is combined with Echothiophate.
Edetic AcidEstrone may decrease the anticoagulant activities of Edetic Acid.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Estrone.
EdrophoniumThe risk or severity of adverse effects can be increased when Estrone is combined with Edrophonium.
EfavirenzThe serum concentration of Estrone can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Estrone can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Estrone.
EnalaprilThe serum concentration of Estrone can be increased when it is combined with Enalapril.
EnoxaparinEstrone may decrease the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Estrone can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Estrone.
EquileninThe serum concentration of Equilenin can be increased when it is combined with Estrone.
EquilinThe serum concentration of Equilin can be increased when it is combined with Estrone.
ErgonovineThe serum concentration of Estrone can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Estrone can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Estrone.
ErythromycinThe metabolism of Estrone can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Estrone.
Eslicarbazepine acetateThe serum concentration of Estrone can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Estrone can be increased when it is combined with Estradiol.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Estrone.
EstramustineThe serum concentration of Estrone can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estrone can be increased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Estrone.
Etacrynic acidEstrone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Estrone can be increased when it is combined with Ethinyl Estradiol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Estrone.
Ethyl biscoumacetateEstrone may decrease the anticoagulant activities of Ethyl biscoumacetate.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Estrone.
EtoposideThe serum concentration of Estrone can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Estrone can be decreased when it is combined with Etravirine.
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Estrone.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Estrone.
FelodipineThe serum concentration of Estrone can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Estrone can be increased when it is combined with Fentanyl.
FenthionThe risk or severity of adverse effects can be increased when Estrone is combined with Fenthion.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Estrone.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Estrone.
FexofenadineThe serum concentration of Estrone can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Estrone.
FidaxomicinThe serum concentration of Estrone can be increased when it is combined with Fidaxomicin.
FloxuridineThe metabolism of Estrone can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Estrone can be decreased when combined with Fluconazole.
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Estrone.
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Estrone.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Estrone.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Estrone.
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Estrone.
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Estrone.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Estrone.
FluorouracilThe metabolism of Estrone can be decreased when combined with Fluorouracil.
FluoxetineThe serum concentration of Estrone can be increased when it is combined with Fluoxetine.
FluoxymesteroneEstrone may increase the fluid retaining activities of Fluoxymesterone.
FlupentixolThe serum concentration of Estrone can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Estrone can be increased when it is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Estrone.
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Estrone.
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Estrone.
FlurazepamThe serum concentration of Estrone can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Estrone.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Estrone.
FluvastatinThe metabolism of Estrone can be decreased when combined with Fluvastatin.
FluvoxamineThe metabolism of Estrone can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumEstrone may decrease the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe metabolism of Estrone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Estrone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Estrone can be decreased when it is combined with Fosphenytoin.
FurosemideEstrone may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Estrone can be increased when it is combined with Fusidic Acid.
GalantamineThe risk or severity of adverse effects can be increased when Estrone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Estrone is combined with Gallamine Triethiodide.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Estrone.
GefitinibThe serum concentration of Estrone can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Estrone.
GemfibrozilThe metabolism of Estrone can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Estrone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Estrone is combined with Ginkgo biloba.
GlyburideThe serum concentration of Estrone can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Estrone can be increased when it is combined with Glycerol.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Estrone.
Gramicidin DThe serum concentration of Estrone can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Estrone.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Estrone.
GrepafloxacinThe serum concentration of Estrone can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Estrone.
HaloperidolThe serum concentration of Estrone can be increased when it is combined with Haloperidol.
HeparinEstrone may decrease the anticoagulant activities of Heparin.
HexestrolThe serum concentration of Estrone can be increased when it is combined with Hexestrol.
HirulogEstrone may decrease the anticoagulant activities of Hirulog.
Huperzine AThe risk or severity of adverse effects can be increased when Estrone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrone.
HydrochlorothiazideEstrone may increase the hypokalemic activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Estrone.
HydroflumethiazideEstrone may increase the hypokalemic activities of Hydroflumethiazide.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Estrone.
IdelalisibThe serum concentration of Estrone can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Estrone.
ImatinibThe metabolism of Estrone can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Estrone.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Estrone.
ImipramineThe serum concentration of Estrone can be increased when it is combined with Imipramine.
IndacaterolIndacaterol may increase the hypokalemic activities of Estrone.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Estrone.
IndapamideEstrone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Estrone can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Estrone.
IndomethacinThe serum concentration of Estrone can be increased when it is combined with Indomethacin.
IrbesartanThe metabolism of Estrone can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Estrone.
IsavuconazoniumThe metabolism of Estrone can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Estrone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Estrone.
IsoniazidThe metabolism of Estrone can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Estrone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Estrone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Estrone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Estrone.
IvermectinThe serum concentration of Estrone can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Estrone can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Estrone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Estrone.
KetoconazoleThe serum concentration of Estrone can be increased when it is combined with Ketoconazole.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Estrone.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Estrone.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Estrone.
LansoprazoleThe serum concentration of Estrone can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Estrone can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Estrone.
LeflunomideThe metabolism of Estrone can be decreased when combined with Leflunomide.
LenalidomideEstrone may increase the thrombogenic activities of Lenalidomide.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Estrone.
LepirudinEstrone may decrease the anticoagulant activities of Lepirudin.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Estrone.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Estrone.
LevofloxacinThe serum concentration of Estrone can be increased when it is combined with Levofloxacin.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Estrone.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Estrone.
LevothyroxineThe serum concentration of Estrone can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Estrone can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Estrone.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Estrone.
LiothyronineThe serum concentration of Estrone can be decreased when it is combined with Liothyronine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Estrone.
LiotrixThe serum concentration of Estrone can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Estrone can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Estrone can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Estrone.
LoperamideThe serum concentration of Estrone can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Estrone can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Estrone can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Estrone.
LosartanThe serum concentration of Estrone can be increased when it is combined with Losartan.
LovastatinThe metabolism of Estrone can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Estrone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Estrone can be decreased when it is combined with Lumacaftor.
MagaldrateThe bioavailability of Estrone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Estrone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Estrone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Estrone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Estrone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Estrone is combined with Malathion.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Estrone.
MaprotilineThe serum concentration of Estrone can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Estrone can be increased when it is combined with Mebendazole.
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Estrone.
MefloquineThe serum concentration of Estrone can be increased when it is combined with Mefloquine.
MefloquineThe risk or severity of adverse effects can be increased when Estrone is combined with Mefloquine.
Megestrol acetateThe serum concentration of Estrone can be increased when it is combined with Megestrol acetate.
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Estrone.
MemantineThe risk or severity of adverse effects can be increased when Estrone is combined with Memantine.
MeprobamateThe serum concentration of Estrone can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Estrone.
MestranolThe serum concentration of Estrone can be increased when it is combined with Mestranol.
MethadoneThe serum concentration of Estrone can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Estrone.
MethyclothiazideEstrone may increase the hypokalemic activities of Methyclothiazide.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Estrone.
MethyltestosteroneEstrone may increase the fluid retaining activities of Methyltestosterone.
MetolazoneEstrone may increase the hypokalemic activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Estrone.
MetoprololThe serum concentration of Estrone can be increased when it is combined with Metoprolol.
MexiletineThe metabolism of Estrone can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Estrone can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Estrone can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Estrone can be decreased when it is combined with Midazolam.
MifepristoneThe therapeutic efficacy of Estrone can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Estrone is combined with Minaprine.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Estrone.
MitomycinThe serum concentration of Estrone can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Estrone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Estrone can be decreased when it is combined with Mitoxantrone.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Estrone.
ModafinilThe serum concentration of Estrone can be decreased when it is combined with Modafinil.
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Estrone.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Estrone.
MorphineThe serum concentration of Estrone can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Estrone.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Estrone.
NadroparinEstrone may decrease the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Estrone can be decreased when it is combined with Nafcillin.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Estrone.
NaltrexoneThe serum concentration of Estrone can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Estrone can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Estrone can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Estrone can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Estrone can be increased when it is combined with Neostigmine.
NeostigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Neostigmine.
NetupitantThe serum concentration of Estrone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Estrone can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Estrone.
NicardipineThe serum concentration of Estrone can be increased when it is combined with Nicardipine.
NicorandilThe risk or severity of adverse effects can be increased when Estrone is combined with Nicorandil.
NicotineThe metabolism of Estrone can be decreased when combined with Nicotine.
NifedipineThe serum concentration of Estrone can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Estrone can be decreased when combined with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Estrone.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Estrone.
NisoldipineThe serum concentration of Estrone can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Estrone can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Estrone can be increased when it is combined with Nitrendipine.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Estrone.
NorethisteroneThe serum concentration of Estrone can be decreased when it is combined with Norethisterone.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Estrone.
OlaparibThe metabolism of Estrone can be decreased when combined with Olaparib.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Estrone.
OmeprazoleThe serum concentration of Estrone can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Estrone can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Estrone.
OspemifeneThe risk or severity of adverse effects can be increased when Estrone is combined with Ospemifene.
OtamixabanEstrone may decrease the anticoagulant activities of Otamixaban.
OxandroloneEstrone may increase the fluid retaining activities of Oxandrolone.
OxymetholoneEstrone may increase the fluid retaining activities of Oxymetholone.
P-NitrophenolThe serum concentration of Estrone can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Estrone.
PaclitaxelThe serum concentration of Estrone can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Estrone can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Estrone can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Estrone.
PantoprazoleThe serum concentration of Estrone can be increased when it is combined with Pantoprazole.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Estrone.
ParoxetineThe serum concentration of Estrone can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Estrone.
Peginterferon alfa-2bThe serum concentration of Estrone can be increased when it is combined with Peginterferon alfa-2b.
PentobarbitalThe serum concentration of Estrone can be decreased when it is combined with Pentobarbital.
Pentosan PolysulfateEstrone may decrease the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe serum concentration of Estrone can be increased when it is combined with Perindopril.
PhenindioneEstrone may decrease the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Estrone can be decreased when it is combined with Phenobarbital.
PhenprocoumonEstrone may decrease the anticoagulant activities of Phenprocoumon.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Estrone.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Estrone.
PhysostigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Physostigmine.
PimozideThe serum concentration of Estrone can be increased when it is combined with Pimozide.
PiretanideEstrone may increase the hypokalemic activities of Piretanide.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Estrone.
Platelet Activating FactorThe serum concentration of Estrone can be decreased when it is combined with Platelet Activating Factor.
Polyestradiol phosphateThe serum concentration of Estrone can be increased when it is combined with Polyestradiol phosphate.
PolythiazideEstrone may increase the hypokalemic activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Estrone.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Estrone.
PonatinibThe serum concentration of Estrone can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Estrone can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Estrone.
PravastatinThe serum concentration of Estrone can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Estrone.
PrazosinThe serum concentration of Estrone can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Estrone.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Estrone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Estrone.
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Estrone.
PrimidoneThe serum concentration of Estrone can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Estrone can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Estrone can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Estrone can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Estrone can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Estrone.
PropranololThe serum concentration of Estrone can be increased when it is combined with Propranolol.
Protein CEstrone may decrease the anticoagulant activities of Protein C.
ProtocatechualdehydeEstrone may decrease the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Estrone can be increased when it is combined with Protriptyline.
PyridostigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Pyridostigmine.
PyrimethamineThe metabolism of Estrone can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Estrone can be increased when it is combined with Quazepam.
QuercetinThe serum concentration of Estrone can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Estrone.
QuinacrineThe serum concentration of Estrone can be increased when it is combined with Quinacrine.
QuinestrolThe serum concentration of Estrone can be increased when it is combined with Quinestrol.
QuinethazoneEstrone may increase the hypokalemic activities of Quinethazone.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Estrone.
QuinidineThe serum concentration of Estrone can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Estrone.
QuinineThe serum concentration of Estrone can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Estrone is combined with Rabies vaccine.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Estrone.
RanitidineThe serum concentration of Estrone can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Estrone can be increased when it is combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Estrone.
ReboxetineThe serum concentration of Estrone can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Estrone can be increased when it is combined with Regorafenib.
ReserpineThe serum concentration of Estrone can be decreased when it is combined with Reserpine.
ReviparinEstrone may decrease the anticoagulant activities of Reviparin.
RifabutinThe serum concentration of Estrone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Estrone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Estrone can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Estrone can be increased when it is combined with Rilpivirine.
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Estrone.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Estrone.
RitonavirThe serum concentration of Estrone can be decreased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Estrone.
RivastigmineThe risk or severity of adverse effects can be increased when Estrone is combined with Rivastigmine.
RolapitantThe serum concentration of Estrone can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Estrone.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Estrone.
RopiniroleThe metabolism of Estrone can be decreased when combined with Ropinirole.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Estrone.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Estrone.
SaquinavirThe serum concentration of Estrone can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Estrone can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Estrone can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Estrone can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Estrone.
SertralineThe serum concentration of Estrone can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Estrone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Estrone.
SiltuximabThe serum concentration of Estrone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Estrone can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Estrone.
SimvastatinThe serum concentration of Estrone can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Estrone can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Estrone.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Estrone.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Estrone.
Somatropin recombinantThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Estrone.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Estrone.
SorafenibThe serum concentration of Estrone can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Estrone.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Estrone.
SpironolactoneThe serum concentration of Estrone can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Estrone can be decreased when it is combined with St. John's Wort.
StanozololEstrone may increase the fluid retaining activities of Stanozolol.
StaurosporineThe serum concentration of Estrone can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Estrone can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Estrone can be decreased when it is combined with Streptozocin.
SulfadiazineThe metabolism of Estrone can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Estrone can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Estrone can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Estrone can be decreased when combined with Sulfisoxazole.
SulodexideEstrone may decrease the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Estrone can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Estrone can be increased when it is combined with Sunitinib.
Synthetic Conjugated Estrogens, AThe serum concentration of Estrone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Estrone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe serum concentration of Estrone can be increased when it is combined with Tacrine.
TacrineThe risk or severity of adverse effects can be increased when Estrone is combined with Tacrine.
TacrolimusThe serum concentration of Estrone can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Estrone can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Estrone.
Taurocholic AcidThe serum concentration of Estrone can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Estrone.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Estrone.
TelaprevirThe serum concentration of Estrone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Estrone can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Estrone can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Estrone.
TemsirolimusThe serum concentration of Estrone can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Estrone can be decreased when combined with Tenofovir.
TerazosinThe serum concentration of Estrone can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Estrone can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Estrone can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Estrone can be decreased when it is combined with Tesmilifene.
TestosteroneEstrone may increase the fluid retaining activities of Testosterone.
TestosteroneThe serum concentration of Estrone can be increased when it is combined with Testosterone.
ThalidomideEstrone may increase the thrombogenic activities of Thalidomide.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Estrone.
TheophyllineThe metabolism of Estrone can be decreased when combined with Theophylline.
ThiotepaThe metabolism of Estrone can be decreased when combined with Thiotepa.
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Estrone.
TiboloneThe serum concentration of Estrone can be increased when it is combined with Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Estrone.
TicagrelorThe serum concentration of Estrone can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Estrone can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Estrone.
TipranavirEstrone may increase the dermatologic adverse activities of Tipranavir.
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Estrone.
TocilizumabThe serum concentration of Estrone can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Estrone can be decreased when combined with Tolbutamide.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Estrone.
TolvaptanThe serum concentration of Estrone can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Estrone.
TorasemideEstrone may increase the hypokalemic activities of Torasemide.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Estrone.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Estrone.
TrazodoneThe serum concentration of Estrone can be decreased when it is combined with Trazodone.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Estrone.
TrichlorfonThe risk or severity of adverse effects can be increased when Estrone is combined with Trichlorfon.
TrichlormethiazideEstrone may increase the hypokalemic activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Estrone can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Estrone can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Estrone can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Estrone can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Estrone can be increased when it is combined with Troleandomycin.
TubocurarineThe risk or severity of adverse effects can be increased when Estrone is combined with Tubocurarine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Estrone.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Estrone.
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Estrone.
Valproic AcidThe metabolism of Estrone can be decreased when combined with Valproic Acid.
ValsartanThe metabolism of Estrone can be decreased when combined with Valsartan.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Estrone.
VemurafenibThe serum concentration of Estrone can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Estrone can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Estrone.
VerapamilThe metabolism of Estrone can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Estrone.
VinblastineThe serum concentration of Estrone can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Estrone.
VinorelbineThe serum concentration of Estrone can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Estrone.
Vitamin CThe serum concentration of Estrone can be increased when it is combined with Vitamin C.
VoriconazoleThe metabolism of Estrone can be decreased when combined with Voriconazole.
WarfarinEstrone may increase the anticoagulant activities of Warfarin.
XimelagatranEstrone may decrease the anticoagulant activities of Ximelagatran.
ZafirlukastThe metabolism of Estrone can be decreased when combined with Zafirlukast.
ZeranolThe serum concentration of Estrone can be increased when it is combined with Zeranol.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Estrone.
ZimelidineThe serum concentration of Estrone can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Estrone can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Margeat E, Bourdoncle A, Margueron R, Poujol N, Cavailles V, Royer C: Ligands differentially modulate the protein interactions of the human estrogen receptors alpha and beta. J Mol Biol. 2003 Feb 7;326(1):77-92. [PubMed:12547192 ]
  2. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. [PubMed:2011412 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. [PubMed:12865317 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Leukotriene-b4 20-monooxygenase activity
Specific Function:
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE).
Gene Name:
CYP4A11
Uniprot ID:
Q02928
Molecular Weight:
59347.31 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Tan E, Lu T, Pang KS: Futile cycling of estrone sulfate and estrone in the recirculating perfused rat liver preparation. J Pharmacol Exp Ther. 2001 Apr;297(1):423-36. [PubMed:11259571 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Noguchi K, Kawahara H, Kaji A, Katayama K, Mitsuhashi J, Sugimoto Y: Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib. Cancer Sci. 2009 Sep;100(9):1701-7. doi: 10.1111/j.1349-7006.2009.01213.x. Epub 2009 May 12. [PubMed:19493273 ]
  2. Kim WY, Benet LZ: P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004 Jul;21(7):1284-93. [PubMed:15290871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Kanai N, Lu R, Bao Y, Wolkoff AW, Vore M, Schuster VL: Estradiol 17 beta-D-glucuronide is a high-affinity substrate for oatp organic anion transporter. Am J Physiol. 1996 Feb;270(2 Pt 2):F326-31. [PubMed:8779894 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Imai Y, Tsukahara S, Asada S, Sugimoto Y: Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004 Jun 15;64(12):4346-52. [PubMed:15205350 ]
  2. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther. 2003 Jan;2(1):105-12. [PubMed:12533678 ]
  3. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043 ]
  4. Imai Y, Asada S, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Breast cancer resistance protein exports sulfated estrogens but not free estrogens. Mol Pharmacol. 2003 Sep;64(3):610-8. [PubMed:12920197 ]
  5. Miwa M, Tsukahara S, Ishikawa E, Asada S, Imai Y, Sugimoto Y: Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants. Int J Cancer. 2003 Dec 10;107(5):757-63. [PubMed:14566825 ]
  6. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res. 2002 Mar;93(3):231-5. [PubMed:11927002 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A: Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res. 2001 Sep;18(9):1262-9. [PubMed:11683238 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23